Why the study?
Conventional cytotoxic drugs are not effective in alveolar soft-part sarcoma, making the efficacy of promising immune checkpoint inhibitors an important area of exploration.
Do immune checkpoint inhibitors improve response rates and survival in patients with advanced alveolar soft-part sarcoma?
Do immune checkpoint inhibitors improve response rates and survival in patients with advanced alveolar soft-part sarcoma?
Immune checkpoint inhibitors demonstrate substantial efficacy in advanced alveolar soft-part sarcoma, providing an overall response rate of 54.4% and prolonged disease control.
No takes yet. Share an insight, caveat, or question.
ICI may yield durable control in advanced ASPS; leaves open need for prospective trials before practice change.
Hindi et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: